Array announces completion of binimetinib and encorafenib transactions
Array BioPharma announced completion of both the binimetinib and encorafenib definitive agreements with Novartis. Along with global ownership of both assets, Array will receive an upfront payment of $85 million from Novartis. March 02, 2015